Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Tipping the balance toward transplantation tolerance: in vivo therapy using a mutated IL-2
Geoffrey Camirand, Fadi G. Lakkis
Geoffrey Camirand, Fadi G. Lakkis
Published March 1, 2024
Citation Information: J Clin Invest. 2024;134(5):e178570. https://doi.org/10.1172/JCI178570.
View: Text | PDF
Commentary Article has an altmetric score of 8

Tipping the balance toward transplantation tolerance: in vivo therapy using a mutated IL-2

  • Text
  • PDF
Abstract

Immune tolerance to allogenic transplanted tissues remains elusive, and therapeutics promoting CD4+FOXP3+ Tregs are required to achieve this ultimate goal. In this issue of the JCI, Efe and colleagues engineered an Fc domain fused to a human mutein IL-2 (mIL-2–Fc) bearing mutations that confer preferential binding to the high-affinity IL-2 receptor expressed on Tregs. In vivo mIL-2–Fc therapy effectively heightened mouse, monkey, and human Treg numbers, promoted tolerance to minor antigen mismatched skin grafts in mice, and synergized with immunosuppressive drugs used in the clinic. These findings warrant clinical trials that assess the efficacy of mIL-2–Fc in transplantation.

Authors

Geoffrey Camirand, Fadi G. Lakkis

×

Figure 1

mIL-2–Fc with trimeric IL-2R specificity induces tolerance in low effector T cell contexts.

Options: View larger image (or click on image) Download as PowerPoint
mIL-2–Fc with trimeric IL-2R specificity induces tolerance in low effect...
The high-affinity trimeric IL-2R is expressed on Tregs and on recently activated effector T cells among others. mIL-2–Fc with specificity for the trimeric IL-2R, but not the dimeric IL-2R expressed on memory T cells and NK cells, expands Tregs in vivo and induces immunological tolerance to minor antigen-mismatched skin grafts in which low effector T cell levels are present at the time of treatment. In contrast, immunological tolerance with mIL-2–Fc treatment cannot be achieved against major antigen-mismatched skin grafts in which elevated effector T cell levels are present at the time of treatment, despite expansion of Tregs.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 14 X users
11 readers on Mendeley
See more details